BRCA2 and ovarian cancer: Oral Contraceptives: The use of oral contraceptives has demonstrated a reduction in the risk of ovarian cancer by up to 45% to 50% in BRCA1-mutation carriers and up to 60% in BRCA2-mutation carriers (McLaughlin et al., 2007).